Gregory G. Schwartz Michael Szarek ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Erin Bohula Lp(a) and CV risk: Insights from the FOURIER trial
Anne Tybjaerg-Hansen Genetics of Lp(a) and CVD
John Chapman Do LDL subfractions matter?
Bo Angelin PCSK9 and the adrenals: how are cholesterol levels protected?
Gerard Pasterkamp Does one plaque characteristic fit all?
Pia Kamstrup Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Francois Mach Low LDL-C and cognitive function: Benefit or harm?
Dirk Müller-Wieland Do low LDL-C levels enhance diabetes risk?
Henry Ginsberg Do low LDL-C levels achieved with statin therapy increase the risk for diabetes mellitus?
J Wouter Jukema ODESSEY OUTCOMES Trial: Topline results
Frederick J. Raal Inclisiran and the ORION Project
Gaetano De Ferrari FOURIER: Timing is everything
Kausik Ray An update on inclisiran
David Hare An update on cardiovascular disease, depression and adherence
Pushkal Garg A background to siRNA: Pushkal Garg, Alnylam
Ulf Landmesser How do we identify very high risk patients for PCSK9 inhibition? Part Two
Erik Stroes How do we identify very high risk patients for PCSK9 inhibition? Part One
Gregory G. Schwartz Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Bertrand Cariou PCSK9 and the beta-cell